CXCR4 and non-small cell lung carcinoma: Peptide R, a novel CXCR4 inhibitor, has demonstrated dual efficacy, it suppresses the dissemination of metastasis-initiating cells, enhances CD8+ T-cell activity, and reduces regulatory T-cell (Treg) infiltration in NSCLC models (74).